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Abstract: Purpose: (1) To determine the contribution of diet, time spent outdoors, and habitual phys-
ical activity (PA) on vitamin D status in men with cerebral palsy (CP) compared to physical activity 
matched controls (TDC) without neurological impairment; (2) to determine the role of vitamin D on 
musculoskeletal health, morphology, and function in men with CP compared to TDC. Materials and 
methods: A cross-sectional comparison study where 24 active, ambulant men with CP aged 21.0 ± 
1.4 years (Gross Motor Function Classification Score (I–II) and 24 healthy TDC aged 25.3 ± 3.1 years 
completed in vivo assessment of musculoskeletal health, including: vastus lateralis anatomical cross-
sectional area (VL ACSA), isometric knee extension maximal voluntary contraction (KE iMVC), 10 
m sprint, vertical jumps (VJ), and radius and tibia bone ultrasound (US) Tus and Zus scores. Assess-
ments of vitamin D status through venous samples of serum 25-hydroxyvitamin D (25(OH)D) and 
parathyroid hormone, dietary vitamin D intake from food diary, and total sun exposure via ques-
tionnaire were also taken. Results: Men with CP had 40.5% weaker KE iMVC, 23.7% smaller VL 
ACSA, 22.2% lower VJ, 14.6% lower KE iMVC/VL ACSA ratio, 22.4% lower KE iMVC/body mass 
(BM) ratio, and 25.1% lower KE iMVC/lean body mass (LBM) ratio (all p < 0.05). Radius Tus and Zus 
scores were 1.75 and 1.57 standard deviations lower than TDC, respectively (p < 0.05), whereas nei-
ther tibia Tus nor Zus scores showed any difference compared to TDC (p > 0.05). The 25(OH)D was 
not different between groups, and 90.9% of men with CP and 91.7% of TDC had low 25(OH)D levels 
when compared to current UK recommendations. The 25(OH)D was positively associated with KE 
iMVC/LBM ratio in men with CP (r = 0.500, p = 0.020) but not in TDC (r = 0.281, p = 0.104). Conclu-
sion: Musculoskeletal outcomes in men with CP were lower than TDC, and despite there being no 
difference in levels of 25(OH)D between the groups, 25 (OH)D was associated with strength (KE 
iMVC/LBM) in the CP group but not TDC. The findings suggest that vitamin D deficiency can ac-
centuate some of the condition-specific impairments to musculoskeletal outcomes. 
Keywords: cerebral palsy; vitamin D; strength; bone; sun exposure 
 
1. Introduction 
Circulating vitamin D levels in vivo can account, in part, for observed variance of 
musculoskeletal outcome measures, with known implications for musculoskeletal impair-
ments resulting from low vitamin D levels in otherwise healthy adults [1]. Predominant 
reasons for reduced vitamin D levels are due to insufficient dietary intake and restricted 
outdoor exposure to sun light [2]. Ultraviolet beta (UV b) radiation from sun exposure 
Citation: Langley, C.K.;  
Onambélé-Pearson, G.L.; Sims, D.T.; 
Hussain, A.; Buffey, A.J.;  
Bardwell, H.L.; Morse, C.I.  
Musculoskeletal Health in Active 
Ambulatory Men with Cerebral 
Palsy and the Impact of Vitamin D. 
Nutrients 2021, 13, 2481. 
https://doi.org/10.3390/nu13072481 
Academic Editor: Giovanni Passeri 
Received: 17 June 2021 
Accepted: 16 July 2021 
Published: 20 July 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and insti-
tutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and 
conditions of the Creative Commons 
Attribution (CC BY) license 
(http://creativecommons.org/licenses
/by/4.0/). 
Nutrients 2021, 13, 2481 2 of 14 
 
 
represents the primary source of endogenous vitamin D (serum 25-hydroxyvitamin D, 
25(OH)D), and, as a result, endogenous vitamin D3 synthesis is severely decreased at lat-
itudes over 35° N during winter months (the UK is ~53° N). Accordingly, individuals at 
these latitudes are susceptible to vitamin D deficiency [1] with 74.5% of the UK population 
exhibiting low vitamin D levels, comprising 33.7% who are vitamin D insufficient 
(25(OH)D levels of 30–20 ng.ml−1) and 40.8% who are vitamin D deficient (25(OH)D < 20 
ng ml−1). 
The current recommendations for dietary intake of vitamin D for UK-based 19–50 
year olds is 400–600 IU per day to benefit musculoskeletal function [3]. Within the general 
UK population, dietary intakes of vitamin D range from 168–291 IU/d (3.5–6.39 μg/d) in 
men and 140–255 IU/d (4.2–7.28 μg/d) in women, contributing to the high levels of the UK 
population who are vitamin D deficient [2]. Only a few foods, such as oily fish, naturally 
contain vitamin D, and these tend to be relatively low dosages [1], meaning it is difficult 
to meet these recommendations through diet alone. As approximately 80% of circulating 
25(OH)D comes from UV b radiation from spending time outdoors in direct sunlight [1], 
it is important that individuals perform outdoor activities in order to accumulate vitamin 
D in replacement of the lack of endogenous vitamin D. Measures of both dietary vitamin 
D analysis [4] and outdoor sunlight exposure are heavily reported with typically devel-
oped, able-bodied adults and children (hereafter termed TDC, typically developed con-
trols) [5,6]. Interestingly, individuals with disabilities, such as cerebral palsy and spinal 
cord injuries, appear to have poorer micronutrients compared to age-matched TDCs (Ole-
son, Patel [7,8]). Furthermore, although not directly related to outdoor activity, physical 
activity (PA) is 48 min lower, and sedentary behaviour is 80 min higher per day in men 
with CP with Gross Motor Function Classification Systems (GMFCS) of I–II compared to 
TDC (Nooijen, Slaman [9]), suggesting a lower level of UV b exposure in individuals with 
CP. Despite physically active individuals reporting higher sun exposure than more sed-
entary individuals, there are many studies that report low 25(OH)D in athletic popula-
tions with and without disabilities. For example, Morton, Iqbal [10] found that elite Eng-
lish Premier League footballers (living at a latitude of 53° N) had low vitamin D (mean ± 
standard deviation (SD), 20.5 ± 7.63 ng∙mL−1) during the winter months, while Flueck, 
Hartmann [11] showed 83.7% of 72 Swiss elite wheelchair athletes (living at a latitude of 
47° N) were vitamin D insufficient. 
The presence of low vitamin D levels in physically impaired groups, such as those 
with CP, is a particular concern given their diminished musculoskeletal health measures, 
such as muscle force production [12,13]. Lower levels of 25(OH)D are associated with 
lower musculoskeletal health outcomes including but not limited to: lower strength [14], 
muscle size [15], reduced bone mass [16], increased parathyroid hormone (PTH) [15], and 
higher levels of adiposity in TDC [17]. Individuals with CP are predisposed to reduced 
muscle size, strength, and bone mass, primarily due to reduced mechanical loading from 
altered gait patterns as a consequence of increased muscle tone and lower range of motion 
[18,19]. These already impaired musculoskeletal outcomes are compromised further in CP 
through modifiable risk factors including poor dietary micronutrient intake [20], reduced 
sun exposure [21], low PA levels [22], and as a side effect of anticonvulsant medications 
[23]. As described, the observed lower vitamin D levels in groups with CP could be a risk 
factor to exacerbated musculoskeletal health, but there appears to be no data pertaining 
to the measurements of vitamin D in PA groups with CP nor its effects on musculoskeletal 
measures. 
Therefore, the aim of this present study was to increase our understanding of the role 
of vitamin D on musculoskeletal health in men with CP and compare it to TDC. The ob-
jectives of this study were to: (1) determine the impact of diet, time spent outdoors, PA, 
and vitamin D status in men with CP compared to TDC without neurological disabilities; 
(2) determine the role of vitamin D on musculoskeletal health in men with CP compared 
to TDC. The hypotheses of this study were: (1) men with CP have lower levels of vitamin 
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D compared to TDC; (2) lower vitamin D leads to reduced musculoskeletal health in men 
with CP. 
2. Materials and Methods 
2.1. Study Protocol 
The study took place in the UK at Manchester and Derby. A total of 48 volunteers 
participated in this study consisting of 24 ambulatory males with CP and 24 male TDC 
(Table 1). All participants provided written informed consent following approval from 
the local Ethics Committee. Participants were assessed for anthropometric measures, mus-
cle size, bone ultrasound Tus and Zus scores, muscle function, dietary vitamin D, total sun 
exposure, and PA (described below). All participants provided venous blood samples for 
subsequent total serum 25(OH)D and serum PTH analysis. 
Table 1. Classification and impairment details of participants. 
  CP Diplegic n = 6 CP Hemiplegic n = 18 CP Total 
n = 24 
TDC 
n = 24 
GMFCS I - 18 18 - 
II 6 - 6 - 
IFCPF classification (FT) 
1 4 - 4 - 
2 2 15 17 - 
3 - 3 3 - 
Side measured Left 5 7 12 4 
Right 1 11 12 20 
GMFCS, Gross Motor Function Classification Score; IFCPF, International Federation of Cerebral Palsy Football. 
All participants were aged 18–30 years old and were UK residents having lived above 
35° N for at least three months prior to this study. The CP group was ambulatory male 
footballers with cerebral palsy playing in the development or the elite disability football 
teams from The Football Association and playing football more than twice per week. Typ-
ically developed control participants were free of any neuromuscular disorder and 
pl6ayed football at least twice per week. Participants were excluded from the study if they: 
reported to have taken vitamin D supplements or used sun beds in the last 3 months prior 
to the study, went on regular holidays (defined as a destination between latitudes of 35° 
N and 35° S with a duration >7 days at a frequency >2 per year), had any illnesses (e.g., 
chronic kidney disease), or were known to be using any medication that may affect the 
metabolism of vitamin D (e.g., corticosteroids). 
2.2. Participants and Recruitment 
Men with CP (diplegic = 6, hemiplegic = 18) were recruited via The Football Associa-
tion and were classified as FT3 (n = 3), FT2 (n = 17) and FT1 (n = 4) with GMFCS between 
I (n = 18) and II (n = 6, Table 1). All participants were tested on a single testing session with 
the same equipment. Testing commenced on 14 February 2019 and ended on 13 March 
2019 for all groups, as total 25(OH)D levels were most likely to be near their nadir in the 
UK population based at a latitude of approximately 53° N [10,24]. 
2.2.1. Anthropometric Measures 
Height (m) was measured using a stadiometer (Seca 213, portable stadiometer, Ham-
burg, Germany) following the stretch-stature method [25] and body mass (BM) (kg) via a 
set of digital scales with minimal clothing (Seca, Hamburg, Germany). Percentages (%) of 
body fat and lean body mass (LBM) were measured using bioelectrical impedance (BIA) 
(Omron, body fat monitor, BF306, Kyoto, Japan). Participants stood upright with their 
arms out on front and gripped the electrodes on each handle. BIA was shown to be valid 
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(R2 = 0.96) in comparison with dual energy X-ray absorptiometry in adult TDC [26] and 
children with CP (concordance correlation coefficient, 0.75–0.82) [27]. It should be noted 
that, where greater variance was reported between BIA and DEXA in CP populations, this 
was attributed in part to errors associated with the use of estimated standing height 
[27,28], whereas, in the present study, all CP participants were able to provide a standing 
height measure. 
2.2.2. Physical Activity 
Habitual PA was recorded through the international physical activity questionnaire-
long form (IPAQ) and presented as IPAQ score. The IPAQ consisted of 27 questions ask-
ing about the amount of time spent performing sedentary behaviours, light intensity 
physical activities, and moderate to vigorous physical activity around travel, work, and 
free time. In addition to PA questions, participants were also asked to answer questions 
on PA around occupation, transport, home, yard/garden, and leisure/sports. To assess ha-
bitual exercise, football training data were logged using 7 day diaries. Data collected in-
cluded frequency of training (days per week), duration of each session (mins), and total 
time spent training (min per week). Step count was also recorded through mobile phone 
accelerometers from those participants (n = 46) with the iPhone Health Application (Apple 
Inc. Cupertino, CA, USA, version 13) as a daily average from the preceding 3 months. 
2.2.3. Muscle Size 
Images of the vastus lateralis (VL) of the impaired leg of hemiplegic CP or the most 
paretic leg of those with diplegic CP and the dominant leg of TDC were obtained using B-
mode ultrasonography with a 7.5 MHz linear array probe (MyLabGamma Portable Ultra-
sound, Esaote Biomedica, Genoa, Italy) to estimate the anatomical cross-sectional area 
(ACSA). As described by Reeves, Maganaris [29], the VL’s proximal insertion and the my-
otendinous junction were marked to identify 50% of muscle length. A strip of echo-ab-
sorptive markers spaced equally apart was placed horizontally around the VL to project 
a shadow onto the ultrasound image to provide a positional reference. With the probe in 
the transverse plane, a recording of the probe moving from the medial border on the VL 
to the lateral border of the VL was obtained. Individual images were extracted from the 
recording and used to construct the muscle by overlapping anatomical landmarks and 
external markers using Microsoft PowerPoint. ImageJ software (Version 1.41, National 
Institutes of Health, Bethesda, MD, USA) was used to measure the cross-sectional area of 
the constructed VL to determine VL ACSA [30]. Reeves, Maganaris [29] validated this 
technique against magnetic resonance imaging (MRI) and showed an inter class correla-
tion (ICC) of 0.99 and mean typical error of 0.3 cm2. Throughout the experimental proce-
dures, all unilateral measures were taken from the paretic side of hemiplegic participants 
and the dominant leg of TDC. In diplegic participants, their most affected side was meas-
ured. Due to time constraints of working with men with CP, it was impossible to measure 
both limbs, however, it should be noted that previous data showed that similar partici-
pants with CP showed no significant difference between their unaffected side and TDC 
[31]. 
2.2.4. Muscle Function 
To assess muscle function, vertical jump (VJ) height (m), maximum sprint time (s), 
grip strength (kg), and isometric knee extension maximal voluntary contraction (KE 
iMVC, N) were measured. Prior to the tests, all participants were taken through a stand-
ardised warm up which aimed to increase heart rate to over 120 bpm (Polar H10 chest 
heart rate monitor, Polar Electro, Kempele, Finland) and dynamic stretches with focus on 
the muscles around hips, knees, and ankles. Participants were given two attempts at each 
test, with 1 min rest in between, and the best result was recorded. VJ height (m) was meas-
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ured using a jump mat (Probotics Inc., Esslinger court, Huntsville, Alabama) in two con-
ditions—with and without arm swing. Nuzzo, Anning [32] reported the jump mat to be a 
reliable piece of equipment to measure VJ height in males (ICC = 0.93, coefficient of vari-
ation (CV) = 2.3%) and females (ICC = 0.90, CV = 6%) over two separate days. 
Maximum sprint speed was assessed over 10 m. Two sets of sensory timing gates 
(Brower timing system, Wireless Sprint System 2007, Brower, Draper, UT, USA) were set 
up 1 m apart at either end of a 10 m distance. Participants performed two sprints with a 
standing start 0.60 m behind the first set of gates. This was shown to be a reliable method 
when measured on two separate days (ICC = 0.912, p < 0.01) [33]. 
Grip strength was assessed using a handgrip dynamometer (Jamar plus, Sammons 
Preston Rolyon, Bolingbrook, IL, USA). Participants chose their most comfortable grip po-
sition, and two maximal grip efforts were performed while standing with the elbow as 
extended as possible and the arm raised in front of the body level with the shoulder. Both 
tests were separated by 1 min, and the highest value was recorded. This current study 
showed a high test-retest reliability in men with CP and TDC (ICC = 0.996–0.998, both p < 
0.001). 
To record KE iMVC, participants were seated on a custom-made isokinetic chair fit-
ted with a portable load cell (Manchester Metropolitan University, Manchester, UK). Their 
arms were across their chest, and the load cell attached around the dominant kicking leg 
(or the most paretic side in the CP group) with the knee at 90° flexion. The tested leg was 
fastened to a force transducer placed 5 cm above the lateral malleolus. Participants were 
instructed to extend the fastened leg maximally, and verbal encouragement was given 
during the measurement. Two trials were performed with 1 min break between each trial. 
The highest force produced was digitised using an analogue-to-digital converter, dis-
played by a self-displayed and coded program (MyLabView, National Instruments, Berk-
shire, UK) [34]. KE iMVC values were also presented relative to VL ACSA (KE 
iMVC/ACSA), BM (KE iMVC/BM), and LBM (KE iMVC/LBM). 
2.2.5. Bone Ultrasound 
Bone ultrasound (US) was used to assess bone Tus and Zus scores (Sunlight, BeamMed 
Ltd., Petah Tikva, Israel) of the distal radius (~5 cm from the condyle) and the distal tibia 
(~12 cm from the condyle). Participants laid supine for both measures. Ultrasound gel was 
applied to the skin surface at the measurement site to facilitate acoustic coupling. To as-
sess the distal radius, the handheld probe was placed in the sagittal plane on the distal 
third of the radius. The probe was rotated ~70° laterally and ~70° distally in the horizontal 
axis around the radius slowly without lifting the probe from the skin surface. The distal 
third of the tibia was measured by placing the probe in the sagittal plane on the anterior 
portion of the tibia. The probe was moved back and forth ~4 cm in the transverse plane 
across the bone without uncoupling the probe from the skin surface. The measurements 
for each procedure were repeated 3–5 times depending on scan quality. After the signal 
was digitised and stored, the data were transferred to a computer for automated analysis, 
and a Tus and Zus score was provided. Knapp, Blake [35] reported that Sunlight ultrasound 
systems have reliable intra-operator precision at distal radius: 0.36% (after 10 consecutive 
scans) and precise in vivo precision: 0.4–0.8% (scans were performed every 2 months for 
2 years). 
2.3. Dietary Vitamin D Assessment 
To assess habitual dietary vitamin D intake, participants completed a 7 day food di-
ary using a mobile phone application (Libro beta, Nutritics, Co. Dublin, Ireland). Partici-
pants logged the weight (g) of food used in all meals and snacks they consumed. This was 
then analysed in Nutritics Software, which provided dietary vitamin D in μg. Day, McKe-
own [36] found that food diary recall was a reliable method for micronutrient intake (R = 
0.75) when compared to urinary markers. 
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Sun Exposure Measurement 
To estimate the level of endogenous skin synthesis of vitamin D3 from sun exposure, 
a sun exposure questionnaire (SEQ) was used to assess frequency, time of day, and 
amount of time that they spent exposed to direct sunlight in spring and summer months 
[37]. Questions also included the type of sun protections that participants habitually used 
that were likely to inhibit vitamin D3 synthesis (i.e., SPF sun cream and clothing worn). To 
obtain a sunlight exposure score, a coded model was used based around the sun exposure 
questions and Fitzpatrick scale to give a total sun exposure (TSE) score for each participant 
[38]. 
2.4. Blood Sample Collection 
Venous blood samples of 5 mL were taken from the antecubital region of the arm for 
all participants. Samples were collected via needle and eccentric luer tip syringe (Terumo 
corporation, Shibuya, Tokyo, Japan), transferred into vacutainer plain tubes (BD Vacu-
tainer Plus® plastic serum tube, Bristol Circle Oakville, ON), and immediately centrifuged 
at 4500 G (Hermle, Model Z380, Countertop Centrifuge, Gosheim, Germany) for 10 min 
to separate the serum. Serum was removed via a micropipette calibrated to 100 μL (Pipet-
man pipette 10–100 μL, Gilson Scientific Ltd., Luton, UK) into two Eppendorf tubes (Ep-
pendorf Tubes® 3810X, Eppendorf, Hamburg) and stored at −20 °C. 
Measurement of Serum 25(OH)D 
Total 25(OH)D concentrations were measured using enzyme-linked immune-sorbent 
assay (ELISA) (Orgentec Diagnostika GmbH, Germany). The Orgentec ELISA showed a 
good correlation of R2 = 0.83 when compared to liquid chromatography mass spectrome-
try (LC-MS/MS) [39]. The manufacturer of the ELISA (Orgentec) provided intra- and inter-
assay CV’s of <14.6% and <11.7%. The intra assay CV for 25(OH)D in our hands was in 
fact lower at 2%. A four-parameter logistic curve also showed a reliable calibration curve 
(optical density vs. concentration (ng∙ml−1) R2 = 0.9819. The Orgentec ELISA was previ-
ously validated against the LC-MS/MS with a bias of 17.8% [40]. 
2.5. Measurement of Parathyroid Hormone 
Serum PTH (PTH) was measured using a 90 min, one-wash ELISA (Abcam, Cam-
bridge, UK). The ELISA had a range of 4.69–300 pg∙mL−1 with a sensitivity of 0.761 
pg∙mL−1. The manufacturer of the ELISA (Abcam, Cambridge, UK) provided intra and 
inter-assay CVs of 1.5% and 3.8%, respectively; the intra-assay CV for PTH from this cur-
rent study was 7.5%. A four-parameter polynomial curve also showed a strong reliability 
score of R2 = 0.9991 in this current study. 
2.6. Statistical Analyses 
Statistics were performed using SPSS statistics (SPSS Statistics 25, IBM Chicago, IL, 
USA). Data were assessed for normal distribution using a Shapiro–Wilks test (p > 0.05). 
Homogeneity of variance was assessed using Levene’s test, and a corrected p value was 
applied if variance was non-homogenous. Group differences for height, BM, BMI, BF%, 
LBM%, dietary intake, TSE, VJ no arms, VJ with arms, 10 m sprint, grip strength, KE 
iMVC/BM, KE iMVC/LBM, and KE iMVC/VL ACSA were assessed by independent T 
tests. Non-parametric group differences for age, tibia Tus and Zus scores, radius Tus and Zus 
scores, VL ACSA, and KE iMVC were assessed using Mann–Whitney U. Pearson correla-
tions were performed to determine any relationships that exist between 25(OH)D and 
diet, UV b exposure, and bone Tus and Zus scores. All data are presented as mean ± SD 
unless otherwise stated, and the confidence interval was set at 95% with alpha set at ≤0.05. 
  




Population Comparisons for CP and TDC 
The CP group was 4.3 years younger (p < 0.001) and had a 14.1% lower BM (p = 0.001), 
a 12.1% lower BMI (p < 0.001), a 20% lower BF% (p = 0.23), and a 20% higher LBM% (p = 
0.023) compared to TDC (Table 2). Although not specifically matched for PA, there were 
no group differences in height, IPAQ, step count, PA frequency, PA average minutes per 
session, or PA total time per week between groups (p > 0.05, Table 2). Pearson’s correla-
tions showed that age was not associated with any outcome measure (all p > 0.05). 
Table 2. Anthropometric and physical activity data in men with cerebral palsy (CP) and PA matched controls (TDC). 
 CP TDC p 
Age (y) 21.0 ± 1.4 25.3 ± 3.1 <0.001 
Height (m)  1.74 ± 0.07 1.76 ± 0.08 0.335 
BM (kg) 66.4 ± 10.1 76.5 ± 10.2 0.001 
LBM (kg) 57.5 ± 9.8 64.0 ± 9.3 0.025 
BMI (kg∙m−2) 21.9 ± 2.1 24.7 ± 2.3 <0.001 
BF% 13.5 ± 4.4 16.5 ± 4.4 0.023 
LBM% 86.5 ± 4.4 83.5 ± 4.4 0.023 
GMFCS (mean (range)) 1.2 (1–2) - - 
IFCPF classification (mean (range)) 2 (1–3) - - 
IPAQ score 8384 ± 4720 7178 ± 5626 0.484 
PA frequency (days/week) 4.00 ± 1.84 4.33 ± 1.86 0.535 
PA duration (mins/session) 65.2 ± 28.3 77.9 ± 17.4 0.066 
PA total time (mins/week) 251.3 ± 135.0 320.2 ± 149.5 0.100 
Step count (steps/day) 8218 ± 3292 6943 ± 2295 0.126 
Reported as mean ±SD and p values; BMI, BM index; BF%, body fat percentage; LBM, lean body mass; GMFCS, Gross 
Motor Function Classification Score; IFCPF, International Federation of Cerebral Palsy Football; IPAQ, international phys-
ical activity questionnaire; PA, physical activity. 
The CP group had a 23.7% smaller VL ACSA (p = 0.001), and KE iMVC was 40.5% 
lower compared to TDC (p < 0.001, Table 3). KE iMVC/VL ACSA, KE iMVC/BM, and KE 
iMVC/LBM were 14.6% (p = 0.048), 22.4% (p = 0.004), and 25.1% (p = 0.002) lower, respec-
tively, in CP compared to TDC (Table 3). The CP group had a 22.2% lower VJ with no arm 
swing and a 21.8% lower VJ with arm swing compared to TDC (p < 0.001 for both (Table 
3). There were no differences in handgrip strength (p = 0.280) or 10 m sprint time between 
CP and TDC (p = 0.302, Table 3). 
Table 3. Neuromuscular outcome measures in men with cerebral palsy (CP) and PA matched controls (TDC). 
 CP TDC p 
VL ACSA (cm2)  27.1 ± 5.4 34.4 ± 8.3 0.001 
KE iMVC (N)  398.8 ± 94.3 601.4 ± 152.4 <0.001 
KE iMVC/VL ACSA (N∙cm−2) 15.2 ± 3.13 17.6 ± 4.15 0.048 
KE iMVC/BM (N∙kg−1) 6.07 ± 1.41 7.60 ± 1.65 0.004 
KE iMVC/LBM (N∙kg−1) 7.11 ± 1.80 9.15 ± 2.06 0.002 
VJ no arms (m) 0.40 ± 0.04 0.50 ± 0.05 <0.001 
VJ with arms (m) 0.45 ± 0.04 0.56 ± 0.05 <0.001 
Grip strength (kg) 39.8 ± 11.9 45.6 ± 7.4 0.280 
10 m sprint (s) 1.90 ± 0.14 1.86 ± 0.12 0.302 
Reported as mean ±SD and p values; VL ACSA, vastus lateralis anatomical cross-sectional area; KE iMVC, knee extensor 
isometric maximal voluntary contraction; BM, BM; VJ, vertical jump. 
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In both groups combined, there was a positive relationship between KE iMVC/LBM 
and jump height (no arms) (R = 0.368, p = 0.021) and VJ (with arm swing) (R = 0.351, p = 
0.029), but KE iMVC/LBM was not associated with 10 m sprint time (R = 0.024, p = 0.881). 
There was, however, no relationship between KE iMVC/LBM and jump height (no arms), 
jump height (with arm swing), or 10 m sprint time in either men with CP (R = 0.232–0.379, 
p > 0.05) or TDC (R = 0.026–0.087, p > 0.05) when grouped separately. 
The CP group had a radius Tus score that was −1.75 SDs less and a radius Zus score 
that was −1.57 SDs less when compared to TDC (p < 0.001, Table 4). There was no differ-
ence between tibia Tus scores (p = 0.158, Table 4) and tibia Zus scores between groups (p = 
0.143, Table 4). A Pearson’s correlation showed that there were no significant relationships 
between 25(OH)D and any tibia or radius Zus and Tus scores for both groups (R = 0.162–
0.253, all p > 0.05). There were also no significant relationships between PTH and any tibia 
or radius Zus and Tus scores for both groups (R = 0.012–0.205, all p > 0.05). 
Table 4. Tibia and radius bone ultrasound (Tus and Zus score) in men with cerebral palsy (CP) and PA matched controls 
(TDC). 
 CP TDC p 
Radius Tus score −1.32 ± 1.12 0.43 ± 0.79 <0.001 
Radius Zus score −0.93 ± 1.12 0.64 ± 0.79 <0.001 
Tibia Tus score  0.50 ± 1.62 −0.03 ± 0.80 0.158 
Tibia Zus score 0.55 ± 1.60 −0.03 ± 0.82 0.143 
Reported as mean ± SD and p values. 
There were no differences in 25(OH)D ng∙mL−1 (p = 0.381), PTH (p = 0.710), dietary 
intake (p = 0.540), or TSE score between groups (p = 0.790, Table 5). Of the men with CP, 
5/22 (22.7%) were classed as severely deficient, 7/22 (31.8%) were deficient, 8/22 (36.4%) 
were insufficient, and 2/22 (9.1%) were adequate in 25(OH)D, while 8/24 (33.3%) of the 
TDC were classed as severely deficient, 9/24 (37.5%) were deficient, 5/24 (20.8%) were in-
sufficient, and 2/24 (8.3%) were adequate in 25(OH)D. Pearson’s correlation showed no 
relationship between 25(OH)D and dietary vitamin D in men with CP (R = 0.079, p = 0.798) 
or TDC (R = 0.165, p = 0.607, Table 5), nor was there a relationship between 25(OH)D and 
TSE in men with CP (R = 0.041, p = 0.857) or TDC (R = 0.167, p = 0.447, Table 5). Pearson’s 
correlation showed that 25(OH)D levels were associated with stronger KE iMVC/LBM (R 
= 0.500, p = 0.020 (1-tailed)) in men with CP (Figure 1), but there was no association be-
tween 25(OH)D and KE iMVC/LBM in TDC (R = 0.281, p = 0.103 (1-tailed), Figure 1). 
Table 5. Vitamin D outcome measures in men with cerebral palsy (CP) and PA matched controls (TDC). 
 CP TDC p 
25(OH)D (ng∙ml−1) 18.7 ± 7.3 16.9 ± 7.1 0.381 
PTH (pg∙ml−1) 25.1 ± 10.2 31.8 ± 14.2 0.710 
Dietary intake (IU∙day−1) 166 ± 186 205 ± 124 0.540 
TSE score 27.4 ± 2.4 28.6 ± 2.1 0.790 
Reported as mean ± SD and p values; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; TSE, total sun exposure. 




Figure 1. Pearson correlations between serum 25(OH)D and KE iMVC/LBM in men with CP (black filled dots) and TDC 
(grey filled dots). 
4. Discussion 
The aim of this study was to increase the understating of vitamin D and musculo-
skeletal health in men with CP. Our findings show that (1) the CP participants had lower 
KE strength, smaller VL ACSA, and lower VJ and sprint performance compared to TDC; 
(2) bone Tus and Zus group comparisons were site-specific to upper and lower limbs, with 
the CP group showing lower radius scores but no difference in the tibia from TDC; (3) 
25(OH)D levels were similar between CP and TDC groups, however, almost all partici-
pants were below levels considered sufficient; and (4) there was a positive association 
between 25(OH)D and KE iMVC/LBM in the CP group but no association in the TDC 
group. 
Due to previous associations between impaired walking and plantar flexors (PF) 
weakness in adults with CP [41], most studies in CP measured PF strength and PF ACSA 
[12,42,43]. However, the KE was deemed an important muscle group to investigate, as 
these muscles play a dominant role in sports performance [44] and fall prevention [45] 
and are limited in their description within CP [46]. The 40.5% lower KE iMVC in the pre-
sent study was consistent with the 52% weaker PF [47] and was a consequence of the PF 
being more directly impacted by the CP condition [12]. In contrast to our more modest 
levels of KE weakness, the previous report of a 69% weaker KE in CP [46] likely reflects 
the sex difference in strength between their mixed sex CP participants compared to their 
male only TDC. In the present study, men with CP had 23.7% smaller VL ACSA, which 
was consistent with the 20% smaller PF ACSA and the 27.9% smaller VL ACSA in men 
with CP compared to TDC (Noble, Fry [42]). The men with CP in this current study had a 
higher LBM% of 86.5% compared to other studies which used BIA in young ambulatory 
males with CP who had an LBM percentage of 74.8% [28]; this could be attributed to the 
high levels of PA in the current men with CP equivalent to 3996 steps more/day when 
compared to other young, ambulatory CP participants [48]. 
A lower knee extensor strength relative to LBM has a number of functional implica-
tions in both CP and other conditions of muscle weakness. Beyond our population of men 
with CP, a lower KEMVC/BM is an observation that was made in a number of conditions 
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erative muscle impairments [51]. Due to the non-progressive nature of CP on neuromus-
cular properties, strategies to train and improve the quality (contractile properties, size, 
and strength) of the effected muscles, particularly the lower limbs, need to be considered 
alongside body fat management to contribute to improved neuromuscular function. 
Surprisingly, there was no difference in 10 m sprint time between groups in the cur-
rent study. A combination of factors may account for the lack of 10 m sprint difference. 
One could be attributed to 18/24 (75%) of the current CP group classifying as GMFCS I. In 
higher GMFC scoring adults with CP, there is increased gait symmetry to TDC [52], which 
could contribute to effective ground reaction force vectors when sprinting [53]. de Groot 
et al. [46] also found no difference in peak power output in a CP group with a GMFCS of 
I when compared to TDC. It should also be considered that the majority of men with CP 
were hemiplegic in this study (Table 1), and running gait patterns were shown to have 
increased symmetry with increasing running speeds [54]. Therefore, peak power output 
and increased sprinting gait symmetry may explain why there was no difference in the 10 
m sprint. 
The bone Tus and Zus score group differences showed site dependence with a lower 
radius T score of −1.32 representing a bone fracture risk of 2.3-fold greater compared to 
normative values [55]; in contrast, the distal tibia showed no difference between groups. 
This was similar to bone Tus and Zus score data presented previously from adolescents 
with CP who had radius and tibia T scores of −1.07 and −0.38, respectively [56]. In adoles-
cents with CP, tibia density was previously reported to be higher with increasing ambu-
lation levels [57]. Indeed, football is specifically effective at preserving age related bone 
Tus and Zus scores in those without CP [58]. It is therefore likely that our observations of 
preserved tibia Tus and Zus scores may be a consequence of regular lower limb bone load-
ing through activities such as football and associated exercise. For future research, it is 
important to acknowledge that the present study does not show that football alone im-
proves bone Tus and Zus scores in men with CP, and more work is required to show this 
association with the sport. It is more probable that the general activity levels of the CP 
group, which included large elements of football, matched Tus and Zus scores of their tibia 
to TDC. Certainly though, clinicians and physical trainers should incorporate exercises 
that load the upper limbs to ensure bone turnover and development occurs in groups with 
CP. 
The lack of difference in PTH between groups was consistent with the fact that almost 
all participants had low levels 25(OH)D [59]. There is a paucity of data on vitamin D con-
centration in disabled populations, particularly in regard to athletes with disabilities, de-
spite low vitamin D concentrations being documented in several nonathletic populations 
[14–16]. Despite our findings that there are no differences in 25(OH)D between the men 
with CP and TDC, both groups were, on average, classified as deficient, with an insuffi-
ciency prevalence of ~90%. These low vitamin D levels relative to summer values are the 
norm in the UK during the winter months [60]. Yet, in the present study, low vitamin D 
levels may exacerbate the condition-specific weakness, e.g., 25(OH)D explained 26% of 
the variance in KE iMVC/LBM in the CP participants. In contrast, we saw no associations 
between 25(OH)D and other outcomes, a likely consequence of the very low levels of 
25(OH)D. This was particularly noticeable in the lack of association between 25(OH)D and 
either dietary vitamin D or TSE in both participant groups, likely as all three could be 
considered very low, e.g., the dietary vitamin D intake (185.5 ± 155 IU/d) was not even 
close to the recommended value of 400–600 IU/d in adults [3]. Similarly, that there was no 
association between TSE and 25(OH)D in this current study was consistent with negligible 
UV b radiation from sun exposure during the latter winter months in the UK (i.e., Febru-
ary–March). Thus, even with the highest TSE scores, 25(OH)D would likely not have been 
high [60]. Despite the negligible 25(OH)D variance between groups, the role of 25(OH)D 
in KE MVC/BM was consistent with the well-established role of 25(OH)D on skeletal mus-
cle myogenesis, cell proliferation, differentiation, regulation of protein synthesis, and mi-
tochondrial metabolism [61]. With this knowledge (and the prevalent insufficiency in all 
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participants), interventions such as vitamin D supplementation should be sought by men 
with both CP and TDC to correct for low vitamin D. In the future, it is important that 
seasonal variations in vitamin D are measured to identify if increased UV b radiation from 
sun exposure improves 25(OH)D to adequate levels and if musculoskeletal health out-
come measures are impacted in men with CP and other para-athletes. 
5. Strengths and Limitations 
The participants in the present study represent a highly functional proportion of men 
with CP (GMFCS I-II). Our participant groups were, however, similar to the only other 
description of KE iMVC and sprint outcomes [46] and were consistent with populations 
of CP athletes investigated by others [62]. Comparisons with population-based studies 
suggest that the proportion of GMFCS I:GMFCSII participants is around n = 3:2 [63]. In 
contrast, the strength comparisons made in the present study as well as the studies by de 
Groot, Dallmeijer [46], and [62] were made in ambulatory participants with CP at a ratio 
of GMFCS I:GMFCS II, n = 3:1, with more severe impairments also included in O’Brien, 
Carroll [62]. The high levels of PA in these active CP participants, however, mean that the 
findings may not be generalisable to other more impaired populations with CP. Although 
a broader population would, of course, be relevant for generalisation, our population of 
lower GMFCS impairment likely reduces the contribution of PA variance to the group 
differences and suggests that, by regularly undertaking football and other forms of PA, 
there is some benefit to the musculoskeletal health of men with CP, particularly in the 
bone Tus and Zus scores of the lower limbs. As addressed throughout these limitations, and 
consistent with the caveat of all studies, the outcomes reflect the population under inves-
tigation. To this end, it is important to note we include no data from women. Although 
not adverse to presenting sex disaggregated musculoskeletal outcomes such as KE 
strength and tendon stiffness [64,65], our recruitment of CP participants was driven by 
the prevailing opportunities for those with CP and, noticeably, a much more limited de-
velopment pathway for women’s para-sport. In previous studies including active CP par-
ticipants where women were presented, it was as a minority (men: women, 2:1 and 4:1, 
respectively [46,66]. Given the known sex differences in bone measures and the greater 
risk for osteoporosis [67], future research should strive to uncover particular risks and 
implications of low vitamin D in women with CP. 
6. Conclusions 
The aim of this study was to increase the understating of vitamin D and musculo-
skeletal health in men with CP. It illustrated that men with CP have lower KE iMVC force, 
smaller VL ACSA, reduced muscle function, and site-specific reduced Tus and Zus scores 
of the radius compared to TDC. Men with CP and TDC are both also at high risk of low 
vitamin D during the winter months, which could contribute to weakness of the KE 
iMVC/LBM in men with CP. Therefore, it is important that men with CP undertake strat-
egies to amend low vitamin D during the winter months such as vitamin D supplementa-
tion to ensure that decreased muscular performance and potential risk of falls from exac-
erbated knee extensor weakness are reduced. 
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IPAQ International Physical Activity Questionnaire 
KE iMVC Knee Extensor Isometric Maximal Voluntary Contraction 
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TDC Typically Developed Controls 
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